GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Cyclically Adjusted FCF per Share

Halozyme Therapeutics (Halozyme Therapeutics) Cyclically Adjusted FCF per Share : $0.69 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.977. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.69 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted FCF Growth Rate was 134.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Halozyme Therapeutics was 55.00% per year. The lowest was -12.90% per year. And the median was 2.40% per year.

As of today (2024-05-17), Halozyme Therapeutics's current stock price is $44.65. Halozyme Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.69. Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is 64.71.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 56.72. And the median was 124.17.


Halozyme Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Cyclically Adjusted FCF per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.35 -0.26 -0.03 0.22 0.56

Halozyme Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.35 0.47 0.56 0.69

Competitive Comparison of Halozyme Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Halozyme Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.977/131.7762*131.7762
=0.977

Current CPI (Mar. 2024) = 131.7762.

Halozyme Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.130 100.560 -0.170
201409 -0.109 100.428 -0.143
201412 -0.009 99.070 -0.012
201503 -0.111 99.621 -0.147
201506 0.065 100.684 0.085
201509 -0.136 100.392 -0.179
201512 -0.131 99.792 -0.173
201603 -0.111 100.470 -0.146
201606 -0.110 101.688 -0.143
201609 -0.072 101.861 -0.093
201612 -0.126 101.863 -0.163
201703 -0.175 102.862 -0.224
201706 -0.129 103.349 -0.164
201709 0.140 104.136 0.177
201712 1.000 104.011 1.267
201803 -0.161 105.290 -0.202
201806 -0.134 106.317 -0.166
201809 -0.134 106.507 -0.166
201812 0.051 105.998 0.063
201903 -0.036 107.251 -0.044
201906 -0.180 108.070 -0.219
201909 -0.210 108.329 -0.255
201912 -0.193 108.420 -0.235
202003 -0.036 108.902 -0.044
202006 0.020 108.767 0.024
202009 0.042 109.815 0.050
202012 0.337 109.897 0.404
202103 0.391 111.754 0.461
202106 0.246 114.631 0.283
202109 0.827 115.734 0.942
202112 0.571 117.630 0.640
202203 0.335 121.301 0.364
202206 0.276 125.017 0.291
202209 0.492 125.227 0.518
202212 0.575 125.222 0.605
202303 0.548 127.348 0.567
202306 0.513 128.729 0.525
202309 0.966 129.860 0.980
202312 0.761 129.419 0.775
202403 0.977 131.776 0.977

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Halozyme Therapeutics  (NAS:HALO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=44.65/0.69
=64.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 56.72. And the median was 124.17.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Halozyme Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Executives
Michael J. Labarre officer: SVP, Chief Technical Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley director, officer: President and CEO C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita director 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley director 1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey officer: SVP, Chief Commerical Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121

Halozyme Therapeutics (Halozyme Therapeutics) Headlines

From GuruFocus

Halozyme Appoints Barbara Duncan to its Board of Directors

By PRNewswire PRNewswire 02-06-2023